


::ODMAMHODMA\iManage;214770;1
HEW/RHU
November 6, 2001



PATENT APPLICATION
Attorney's Docket No.: 1855.1017-000 (LKS95-10)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Paul D. Ponath, Douglas J. Ringler, S. Tarran Jones, Walter Newman,
Jose Saldanha and Mary M. Bendig

Application No.: 08/700,737 Group: 1644

Filed: August 15, 1996 Examiner: P. Gambel

For: HUMANIZED IMMUNOGLOBULIN REACTIVE WITH $\alpha 4\beta 7$ INTEGRIN

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231	
on <u>11.12.01</u>	<u>Danielle D. Gath</u>
Date	Signature
<u>Danielle D. Gath</u>	
Typed or printed name of person signing certificate	

DECLARATION OF WALTER NEWMAN, Ph.D. UNDER 37 C.F.R. § 1.132

Assistant Commissioner for Patents
Washington, D.C. 20231

I, Walter Newman, Ph.D., of 3 Durham Street, Apartment 3, Boston, Massachusetts
02115, hereby declare and state that:

1. I was an employee of LeukoSite, Inc., an assignee of the above-referenced patent application, from 1993 until December 1999. I was Director of Research at LeukoSite, Inc. from 1993 until 1997 and then became Senior Vice President, Research, Monoclonal Antibody Discovery and Preclinical Development. Following the merger of LeukoSite, Inc. and Millennium Pharmaceuticals, Inc. in December 1999, I became Senior Vice President, Biotherapeutics, Millennium Pharmaceuticals, Inc. I remained Senior Vice President, Biotherapeutics, Millennium Pharmaceuticals, Inc. until September 2001, when I left the company to pursue other opportunities.
2. I am an inventor of the above-referenced patent application and I am familiar with the application, the invention claimed therein and the Office Action mailed April 4, 2000.
3. In March of 1995, LeukoSite, Inc. entered into a License Agreement with The General Hospital Corporation, a not-for-profit corporation doing business as Massachusetts General Hospital, under which LeukoSite, Inc. was granted an exclusive license to the Act-1 hybridoma cell line for the purpose of making, having made, using and selling antibody derived from the Act-1 hybridoma cell line and antibody conjugates in the field of use. Subject to the terms of the agreement, a sample of the Act-1 hybridoma cell line was provided to LeukoSite, Inc.
4. After LeukoSite, Inc. and The General Hospital Corporation entered into the License Agreement, Dr. Lazarovits forwarded requests for samples of the Act-1 monoclonal antibody or Act-1 hybridoma cell line that he received to me for consideration.
5. In March 1996, I contacted Dr. Lazarovits to confirm whether the Act-1 hybridoma cell line had been distributed to others. Dr. Lazarovits stated that he had not distributed the Act-1 hybridoma cell line.

6. LeukoSite, Inc. did not distribute samples of the Act-1 hybridoma cell line.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.



Walter Newman, Ph.D.



Date